Plant Name: Ursinia anthemoides
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.054E-12 | 2.237E-08 | CYP19A1, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.047E-10 | 7.602E-07 | CYP19A1, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.600E-10 | 9.436E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.600E-10 | 9.436E-07 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.309E-09 | 3.166E-06 | CYP19A1, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.716E-09 | 4.550E-06 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.622E-09 | 6.486E-06 | CYP19A1, CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.027E-09 | 6.486E-06 | CYP19A1, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 5.282E-08 | 5.001E-05 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 8.120E-08 | 6.801E-05 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.070E-07 | 2.228E-04 | CA12, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 8.942E-07 | 6.281E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.743E-06 | 1.150E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 2.459E-06 | 1.487E-03 | CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.759E-06 | 2.801E-03 | CA12, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.786E-06 | 4.666E-03 | CA12, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.294E-15 | 4.995E-11 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.489E-09 | 1.291E-07 | CYP2C9; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.075E-08 | 1.989E-07 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.004E-07 | 3.558E-06 | CYP2C9; CYP1A2; ALDH1A1; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.808E-07 | 3.558E-06 | CYP2C9; CYP2D6; CYP1A2; CYP3A4 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 5.303E-06 | 2.803E-05 | CYP2C9; ODC1; CYP1A2; ALDH1A1; CYP2C19; CYP3A4; CYP19A1; HSD17B10 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 7.687E-07 | 4.740E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 4.130E-07 | 3.558E-06 | CA12; CA7; CA9 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.831E-05 | 8.469E-05 | CYP1A2; CYP3A4; CYP19A1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.312E-04 | 5.394E-04 | CYP2C9; CYP2D6; CYP2C19 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.104E-03 | 4.086E-03 | CASP7; CASP1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.401E-03 | 4.713E-03 | CYP2C9; CYP2C19 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.042E-03 | 6.296E-03 | CASP7; CASP1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 6.916E-03 | 1.828E-02 | CASP7; LMNA |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 9.825E-03 | 2.423E-02 | CASP7; HSD17B10 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.492E-03 | 1.279E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9 |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA9 |
| A00-B99: Certain infectious and parasitic diseases | Burns and burn infection | A00-B99 | ODC1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | African trypanosomiasis | B56 | ODC1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | ODC1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |